November 28, 2005 -- American Pharmaceutical Partners took a hit after announcing a plan to simplify its complicated corporate structure and buy its parent firm; Merck announced a major restructuring that will cut 7,000 employees or 11% of its workforce; Seriologicals signed a license with RheoGene for its system that regulates the timing and amount of gene expression; BioCryst filed its application with the FDA to test a Tamiflu-like flu drug; Targeted Genetics won a $18 million contract to develop an HIV vaccine; Pozen won UK approval for MT 100, its treatment for acute migraine; and IDM Pharma sold its infectious disease program to Pharmexa A/S for $12 million. The Centient Biotech 200™ suffered its worst loss in almost two months, trading 73 points lower to 3938.37, a drop of 1.82%. More details...